(Q38777707)

6 September 2017

title

Interferon, tryptophan and depression (English)

1 reference

6 September 2017

D Fekkes

1

1 reference

6 September 2017

A R Van Gool

series ordinal

2

1 reference

6 September 2017

publication date

1 February 2003

1 reference

6 September 2017

published in

Acta Neuropsychiatrica

1 reference

6 September 2017

volume

15

1 reference

6 September 2017

issue

1

1 reference

6 September 2017

page(s)

8-14

1 reference

Mood-lowering effect of tryptophan depletion. Enhanced susceptibility in young men at genetic risk for major affective disorders.

6 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1034%2FJ.1601-5215.2003.00007.X

Plasma L-tryptophan/neutral amino acid ratio and dexamethasone suppression in depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1601-5215.2003.00007.X

Effects of interferon-alpha, interferon-gamma and cAMP on the transcriptional regulation of the serotonin transporter

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1601-5215.2003.00007.X

Platelet serotonin and plasma tryptophan decreases in endogenous depression. Clinical, therapeutic, and biological correlations

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1601-5215.2003.00007.X

Brain serotonin content: physiological dependence on plasma tryptophan levels.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1601-5215.2003.00007.X

Association between decreased serum tryptophan concentrations and depressive symptoms in cancer patients undergoing cytokine therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1601-5215.2003.00007.X

Increased depressive ratings in patients with hepatitis C receiving interferon-alpha-based immunotherapy are related to interferon-alpha-induced changes in the serotonergic system

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1601-5215.2003.00007.X

Immunotherapy with interferon-alpha in patients affected by chronic hepatitis C induces an intercorrelated stimulation of the cytokine network and an increase in depressive and anxiety symptoms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1601-5215.2003.00007.X

Association between immune activation and early depressive symptoms in cancer patients treated with interleukin-2-based therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1601-5215.2003.00007.X

Neurobehavioral effects of interferon-alpha in cancer patients: phenomenology and paroxetine responsiveness of symptom dimensions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1601-5215.2003.00007.X

Treatment with interferon-alpha (IFN alpha) of hepatitis C patients induces lower serum dipeptidyl peptidase IV activity, which is related to IFN alpha-induced depressive and anxiety symptoms and immune activation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1601-5215.2003.00007.X

Neuropsychiatric symptoms associated with hepatitis C and interferon alpha: A review

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1601-5215.2003.00007.X

Paroxetine for the prevention of depression induced by high-dose interferon alfa

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1601-5215.2003.00007.X

Psychiatric side effects of interferon therapy: prevalence, proposed mechanisms, and future directions

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1601-5215.2003.00007.X

Hormone responses to fenfluramine and placebo challenge in endogenous depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1601-5215.2003.00007.X

Management of psychiatric adverse events with immunotherapy with interferon-alfa

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1601-5215.2003.00007.X

Evidence for an immune response in major depression: a review and hypothesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1601-5215.2003.00007.X

Ritanserin attenuates anorectic, endocrine and thermic responses to d-fenfluramine in human volunteers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1601-5215.2003.00007.X

Cytokines and the brain: implications for clinical psychiatry

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1601-5215.2003.00007.X

5HT2 receptors, depression and anxiety

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1601-5215.2003.00007.X

Endotoxin produces a depressive-like episode in rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1601-5215.2003.00007.X

Decreased plasma tryptophan concentration in major depression: relationship to melancholia and weight loss

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1601-5215.2003.00007.X

Relapse of depression after rapid depletion of tryptophan.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1601-5215.2003.00007.X

Interferons, serotonin and neurotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1601-5215.2003.00007.X

Current advances and trends in the treatment of depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1601-5215.2003.00007.X

Brain Serotonin1A Receptor Binding Measured by Positron Emission Tomography With [11C]WAY-100635

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1601-5215.2003.00007.X

Predictive value of tryptophan/large neutral amino acids ratio to antidepressant response.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1601-5215.2003.00007.X

Plasma tryptophan to large neutral amino acids ratio and therapeutic response to a selective serotonin uptake inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1601-5215.2003.00007.X

Free and total plasma tryptophan in endogenous depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1601-5215.2003.00007.X

Plasma tryptophan levels and plasma tryptophan/neutral amino acids ratio in patients with mood disorder, patients with obsessive-compulsive disorder, and normal subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1601-5215.2003.00007.X

Lowered Serum Dipeptidyl Peptidase IV Activity is Associated with Depressive Symptoms and Cytokine Production in Cancer Patients Receiving Interleukin-2-Based Immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1601-5215.2003.00007.X

Antidepressant response reversed by interferon

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1601-5215.2003.00007.X

Decreased plasma tryptophan levels in major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1601-5215.2003.00007.X

Plasma tryptophan and five other amino acids in depressed and normal subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1601-5215.2003.00007.X

Interferon-alpha-induced biologic modifications in patients with chronic myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1601-5215.2003.00007.X

Plasma prolactin changes following fenfluramine in depressed patients compared to controls: an evaluation of central serotonergic responsivity in depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1601-5215.2003.00007.X

5-HT and mechanisms of defence

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1601-5215.2003.00007.X

Considering depression as a consequence of activation of the inflammatory response system

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1601-5215.2003.00007.X

Effects of bacterial endotoxin on the glucocorticoid feedback regulation of adrenocortical response to stress

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1601-5215.2003.00007.X

Relationships between lower plasma L-tryptophan levels and immune-inflammatory variables in depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1601-5215.2003.00007.X

Decreased plasma serotonin in melancholic patients: A study with clomipramine

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1601-5215.2003.00007.X

Effects of clomipramine on plasma amino acids and serotonergic parameters in panic disorder and depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1601-5215.2003.00007.X

Relationship between the dexamethasone suppression test and the L-tryptophan/competing amino acids ratio in depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1601-5215.2003.00007.X

Cytokine mediated regulation of interferon-gamma-induced IDO activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1601-5215.2003.00007.X

7 January 2021

Total and non-bound tryptophan in unipolar illness

1 reference

https://api.crossref.org/works/10.1034%2FJ.1601-5215.2003.00007.X

7 January 2021

Effect of single intracerebroventricular injection of alpha-interferon on monoamine concentrations in the rat brain

1 reference

https://api.crossref.org/works/10.1034%2FJ.1601-5215.2003.00007.X

7 January 2021

Prolactin and cortisol responses to d-fenfluramine in major depression: evidence for diminished responsivity of central serotonergic function

1 reference

https://api.crossref.org/works/10.1034%2FJ.1601-5215.2003.00007.X

7 January 2021

10.1034/J.1601-5215.2003.00007.X

Identifiers

DOI

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/pzrzau67nfcdlarqmww3e2i3ti

30 July 2022

mapped directly with Wikidata item

Fatcat ID

release_pzrzau67nfcdlarqmww3e2i3ti

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/pzrzau67nfcdlarqmww3e2i3ti

30 July 2022

mapped directly with Wikidata item

https://api.fatcat.wiki/v0/release/pzrzau67nfcdlarqmww3e2i3ti

1 reference

30 July 2022